GlassScriptPhysician profile
Elizabeth A Tracy
NPI 1699757591
$2,060.29
in general payments reported to CMS, 2019-2025
24 companies · $408 in 2025
The $408 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $121 · 2021: $293 · 2022: $256 · 2023: $261 · 2024: $226 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $894.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $384.28 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $336.05 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $297.46 | 2019-2025 | |
| Amgen INC. | $148.95 | 2023-2025 | Evenity, Prolia, Otezla |
| Sanofi-Aventis U.S. LLC | $124.90 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.65 | 2019-2022 | |
| Abbott Laboratories | $86.82 | 2023-2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $78.61 | 2023-2025 | Arexvy, Shingrix, Bexsero |
| Amarin Pharma, INC. | $62.74 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $55.02 | 2020-2024 | Gardasil, Gardasil 9, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $51.76 | 2021-2025 | Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $44.04 | 2022 | |
| Novartis Pharmaceuticals Corporation | $35.72 | 2019-2023 | |
| Intuity Medical INC | $27.78 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Teva Pharmaceuticals USA, INC. | $27.63 | 2019-2024 | Austedo Xr |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $26.83 | 2021 | |
| Exact Sciences Corporation | $26.11 | 2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $22.57 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $22.46 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $20.30 | 2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $17.63 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.07 | 2023 | Seglentis |
| Bayer Healthcare Pharmaceuticals INC. | $13.61 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Tracy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.